Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis (Q45397328)

14 December 2017

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis (English)

1 reference

14 December 2017

0 references

1 reference

6

Martin F Bachmann

1 reference

14 December 2017

Gunther Spohn

1

1 reference

14 December 2017

Iris Keller

2

1 reference

14 December 2017

Markus Beck

3

1 reference

14 December 2017

Paula Grest

4

1 reference

14 December 2017

Gary T Jennings

5

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

European Journal of Immunology

14 December 2017

1 reference

14 December 2017

38

1 reference

14 December 2017

877-887

1 reference

14 December 2017

3

1 reference

Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles

14 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

The epistatic interrelationships of IL-1, IL-1 receptor antagonist, and the type I IL-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

https://api.crossref.org/works/10.1002%2FEJI.200737989

1 reference

7 January 2021

The balance between IL-1 and IL-1Ra in disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

The influence of antigen organization on B cell responsiveness

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

IgG autoantibodies against interleukin 1 alpha in sera of normal individuals

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Arthritis induced with cartilage-specific antibodiesis IL-4-dependent.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Variation in IL-1beta gene expression is a major determinant of genetic differences in arthritis aggressivity in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Arthritis critically dependent on innate immune system players

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Granulomatous infections due to tumor necrosis factor blockade: correction

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737989

7 January 2021

Identifiers

DOI

10.1002/EJI.200737989

1 reference

14 December 2017

1 reference